Related Experiment Video
Updated: Mar 14, 2026
A Saline/Bipolar Radiofrequency Energy Device As an Adjunct for Hemostasis in Solid Organ Injury/Trauma
Published on: July 28, 2020
Safety and efficacy of tranexamic acid in bleeding paediatric trauma patients: a systematic review protocol
Denisa Urban1, Ruben Dehaeck2, Diane Lorenzetti3
1Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Insights
Tranexamic acid (TxA) shows promise for controlling bleeding in pediatric trauma patients. This review evaluates its current use, benefits, and risks in children, addressing a gap in current medical knowledge.
Area of Science:
- Pediatric trauma care
- Pharmacology
- Hemorrhage control
Background:
- Trauma is a leading cause of death in children.
- Effective bleeding control could prevent 10-20% of trauma deaths.
- Tranexamic acid (TxA) is effective in adult trauma but understudied in children.
Purpose of the Study:
- To review the current applications of TxA in pediatric trauma.
- To evaluate the benefits and adverse effects of TxA in bleeding children.
- To address the sparse data on TxA's efficacy in pediatric populations.
Main Methods:
- Systematic literature search of multiple databases (MEDLINE, EMBASE, PubMed, CINAHL, Cochrane CENTRAL).
- Inclusion of randomized controlled trials and cohort studies on TxA in pediatric trauma.
- Data extraction and risk of bias assessment performed independently and in duplicate.
Main Results:
- This section is not applicable as the study is a review and does not present primary data.
- The review synthesizes existing evidence on tranexamic acid in pediatric trauma.
- Potential benefits and adverse effects will be analyzed based on retrieved studies.
Conclusions:
- Further research is needed to establish definitive guidelines for TxA use in pediatric trauma.
- This review aims to consolidate current evidence to inform clinical practice.
- Understanding TxA's role can improve outcomes for bleeding pediatric trauma patients.
Introduction:
Trauma is the leading cause of death among children aged 1-18. Studies indicate that better control of bleeding could potentially prevent 10-20% of trauma-related deaths. The antifibrinolytic agent tranexamic acid (TxA) has shown promise in haemorrhage control in adult trauma patients. However, information on the potential benefits of TxA in children remains sparse. This review proposes to evaluate the current uses, benefits and adverse effects of TxA in the bleeding paediatric trauma population.
Methods And Analysis:
A structured search of bibliographic databases (eg, MEDLINE, EMBASE, PubMed, CINAHL, Cochrane CENTRAL) has been undertaken to retrieve randomised controlled trials and cohort studies that describe the use of TxA in paediatric trauma patients. To ensure that all relevant data were captured, the search did not contain any restrictions on language or publication time. After deduplication, citations will be screened independently by 2 authors, and selected for inclusion based on prespecified criteria. Data extraction and risk of bias assessment will be performed independently and in duplicate. Meta-analytic methods will be employed wherever appropriate.
Ethics And Dissemination:
This study will not involve primary data collection, and formal ethical approval will therefore not be required. The findings of this study will be disseminated through a peer-reviewed publication and at relevant conference meetings.
Trial Registration Number:
CRD42016038023.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution